CONNECT Trial CGM Type 2 Diabetes: Results and Study Limits

What the CONNECT Trial Tested

The CONNECT randomized controlled trial compared the Dexcom G7 continuous glucose monitor with routine care in adults with type 2 diabetes who do not take insulin. The full paper, titled "CGM for Adults with Type 2 Diabetes Not on Insulin: The CONNECT Randomized Controlled Trial" (Oser T, et al.), was published in The New England Journal of Medicine. Study investigators first presented the trial data on June 6, 2026, in New Orleans at the American Diabetes Association (ADA) Scientific Sessions, before Dexcom issued its formal publication release on October 14, 2026.

The trial took place in US primary care. Study teams screened 440 individuals across 22 US primary care sites. The population was adults with type 2 diabetes who were not on insulin. Dexcom's announcement did not report how many of those 440 screened individuals were randomized or included in the final analysis.

The intervention assigned participants to wear the Dexcom G7 continuous glucose monitor for 26 weeks. The control group continued with their routine clinical care over the same 26 weeks.

What It Found

Across the 26-week study period, participants using the Dexcom G7 continuous glucose monitor lowered their glycated hemoglobin by 1.6 points from a mean baseline of 8.8%, which was 0.9 points more than the reduction in the routine-care group. Dexcom's announcement did not report the specific A1C reduction achieved by the routine-care arm alone. The sensor group spent approximately five more hours per day in the 70 to 180 mg/dL range compared with the routine-care group. This daily improvement appeared within the first week of starting the device. Of participants, 97% were still using the sensor at 26 weeks, most of them daily.

Who Benefited

Dexcom reports that the CONNECT benefit appeared among participants taking glucagon-like peptide-1 (GLP-1) medicines. Among participants taking a GLP-1 medication, adding continuous glucose monitoring yielded an additional 0.9-point A1C reduction compared with routine care. Across all participants, the largest difference was in people on a GLP-1 only at baseline, a 1.3-point difference between the sensor group and the control group.

Dexcom's press release reports benefit across age, sex, race and ethnicity, and BMI. Dexcom also reports benefit across diabetes duration, income, education, health insurance, and glucose-lowering medications.

What the Trial Does Not Show

Dexcom's announcement does not report safety findings or funding, and the 26-week trial does not show whether the improvements last longer. Most of the numbers on this page come from the Dexcom announcement of the CONNECT study rather than a reading of the full New England Journal of Medicine paper.

Because the trial duration was limited to 26 weeks, the data do not demonstrate whether participants maintain daily sensor wear or glycemic control past 26 weeks. Dexcom also did not report the exact numerical change in A1C for the routine-care group, sharing only the relative difference between groups.

Access and Guidelines

Although Dexcom says the CONNECT results add to evidence supporting broader access, Dexcom's announcement cites no change to insurance coverage or clinical practice guidelines. Senior author Roy W. Beck, MD, PhD, of the JAEB Center for Health Research, said the findings support consideration of continuous glucose monitors much earlier in care. Dexcom's chief executive officer urged physicians, payors, and healthcare leaders to recognize the impact of sensor technology in this group, and Dexcom says the results add to evidence supporting broader access.